Treatment of infection by human enterovirus D68
The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.
1. A method of treating infection by EV-D68 in a patient, the method comprising administering by inhalation to the patient an effective amount of DAS181.
2. The method of claim 1 wherein the DAS181 is administered to the patient before the patient exhibits a symptom of infection by EV-D68.
3. The method of claim 1 comprising administering a composition comprising microparticles comprising DAS181.
4. The method of claim 1 wherein the patient suffers from asthma or is immunocompromised.
5. The method of claim 1 further comprising administering a capsid inhibitor.
6. The method of claim 1 further comprising administering an agent selected from the group consisting of: pleconaril, pocapavir, vapendavir, KR-22865, rupintrivir, V-7404, amantadine, arbidol, favipiravir, oseltamivir, fluoxetine, formoterol fumarate, itraconazole, mefloquine, and nitazoxanide.